Novartis Message Board - Msg: 12188054

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 123.83

+1.0%

Oct 31 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: gao seng who wrote (253)	12/4/1999 1:02:00 PM
From: Grateful Reaper	Read Replies (1) of 296

It sounds like the principle used to develop STI-571 may be applicable to other cancer drugs developed in the future, but this particular drug, STI-571, was designed to treat one form of leukemia with only 4,300 cases in the U.S. each year. The potential income from this drug seems relatively small for a company the size of Novartis. This is not some obscure biotech whose shares have lots of room to skyrocket as a result of this widely-reported, seemingly sensational news. Novartis currently seems to be fully valued at $80 per ADR. Also, it looks like the ADRs (NVTSY) trade on the OTC bulletin board.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next